Goldman Sachs
RGNX icon

Goldman Sachs’s Regenxbio RGNX Stock Holding History

Goldman Sachs’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-29,100
Closed -$1.04M – 5380
2019
Q3 		$1.04M Buy
+29,100
New +$1.18M ﹤0.01% 4005
2018
Q2 		– Sell
-40,000
Closed -$1.19M – 5954
2018
Q1 		$1.19M Buy
+40,000
New +$1.16M ﹤0.01% 3935

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's RGNX Position: Q2 2026 in Review

Goldman Sachs reduced its Regenxbio (RGNX) stake by 23% in Q2 2026, selling an estimated $3.47M and leaving 1,421,453 shares worth $17M. The position accounts for ﹤0.01% of the portfolio, ranked #2803.

Goldman Sachs first reported a position in RGNX in Q2 2016 and has held it in 41 quarters since. The position peaked at $33.1M in Q4 2020. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • Goldman Sachs held 1,421,453 shares of Regenxbio worth $17M as of Q2 2026.
  • Goldman Sachs sold 418,010 Regenxbio shares in Q2 2026, an estimated $3.47M.
  • Regenxbio made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2803 holding.
  • Goldman Sachs first reported a position in Regenxbio in Q2 2016 and has held it in 41 quarters since.
  • Goldman Sachs's Regenxbio position peaked at $33.1M in Q4 2020.
  • 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.